Bausch & Lomb Incorporated

Other

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

123

Clinical Trials↗

All sponsored trials (all statuses)

Pipeline

Pipeline Snapshot

By Phase

4 drugs in development

Approved1

Phase 24

Preclinical1

By Therapeutic Area

top 3

Ophthalmology

467%

Cardiovascular

117%

Immunology

117%

R&D Momentum

37/100

Pipeline Velocity

22/100

Trial Completion Rate

92/100

Pipeline Concentration

50/100

Pipeline Freshness

91/100

Strategic Signals

↗Early-stage heavy pipeline may seek late-stage partners
↗Active in Cardiovascular but thin pipeline — potential licensing opportunity

Activity

Recent Activity

Last 14 days

Jul 14, 2026

Completed

A Prospective, Multicenter, Randomized, Controlled Clinical Study to Evaluate the Safety and Effectiveness of the enVista® Beyond (EY) EDF Intraocular Lens in Subjects Undergoing Cataract Extraction

Jul 7, 2026

Completed

A Phase 4, Multicenter, Open-Label Study to Evaluate the Effect of Miebo™ on Preoperative Biometry/ Keratometry and Postoperative Refractive Accuracy

Earlier

Apr 1, 2026TrialA Study to Evaluate the Use of Topical Ocular BL1332 for the Management of Postoperative Ocular Pain Following Photorefractive Keratectomy

Dec 1, 2025TrialA Study to Assess the Long-Term Safety of Lifitegrast/Perfluorohexyloctane Fixed-Dose Combination in Subjects With Dry Eye Disease

Oct 24, 2025TrialA Study Evaluating the Safety and Efficacy of a Fixed-Dose Combination for Dry Eye Disease

Oct 24, 2025TrialPhase 2 Study of BL1107 Eye Drops vs. Timolol in Adults With Primary Open Angle Glaucoma or Ocular Hypertension

Jul 29, 2025TrialA Study to Assess Safety, Tolerability, and Pharmacokinetics of Ascending Concentrations of Topical Ocular BL1332 in Healthy Volunteers

Jul 2, 2025TrialA Study to Evaluate Concomitant Perfluorohexyloctane Use With Contact Lens Wear

4 more events

May 22, 2025TrialA Study Comparing the Efficacy and Safety of Brimonidine Tartrate Ophthalmic Solution 0.025% With Sodium Hyaluronate Relative to Lumify in Adult Subjects With Ocular Redness

Jul 31, 2024TrialA Study to Evaluate Corneal Endothelial Cell Density (ECD) in Subjects With Dry Eye Disease (DED) Administering Miebo® (Perfluorohexyloctane Ophthalmic Solution) for 12 Months.

Feb 28, 2024TrialA Study to Evaluate Early Treatment Outcomes With Miebo™ in Subjects With Dry Eye Disease

Aug 14, 2023TrialEffects of NOV03 on the Tear Film

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Pipeline

Drug Pipeline

Indication

Preclinical

Phase 1

Phase 2

Phase 3

Approved

XiidraPhase 2

Ophthalmology

Cataract

XiidraPreclinical

Dry Eye

MieboApproved

Eye Disease

MieboApproved

XiidraPhase 2

MieboPhase 2

Ocular Pain

Topical Ocular BL1332 low dosePhase 2

Regulatory

Regulatory Timeline

20041 event

FDAMay 5

VITRASE — VITRASE

Application BLA021640 (BLA)

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)